In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CUV" target="_blank" >RIV/61988987:17110/21:A2202CUV - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/21:00075089 RIV/00843989:_____/21:E0109155 RIV/61989592:15110/21:73611284 RIV/00216224:14110/21:00124158

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000694709000003" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000694709000003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33678/cor.2021.013" target="_blank" >10.33678/cor.2021.013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

Popis výsledku v původním jazyce

Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR

Název v anglickém jazyce

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

Popis výsledku anglicky

Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor Et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

63

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

6

Strana od-do

442-447

Kód UT WoS článku

000694709000003

EID výsledku v databázi Scopus

—